On November 21st, Tianjin Pharmaceutical Holdings Co., Ltd. held a seminar on the development of Tianjin Pharmaceutical Internationalization in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. The seminar was conducted with a purpose to broaden the horizons and provide export reference for enterprises of the group, and to promote enterprises to think strategically based on the current export business situation, find the target opportunities in the international market, and form a suitable and feasible development plan.

On the meeting, Xu Ming, director of the Department of Global Health of Peking University School of Public Health and vice president of Global Health Development Research Institute, Wu Huifang, general manager of Beijing Orientbit Technology Co., Ltd. (Health Net), Shi De, vice president of Indian Cipla Company and head of China District, Amit Kaptain, president of Indian Ami Lifesciences Company, Hong Tan, partner of Legend Capital, and other industry experts were invited to attend the meeting and share on the meeting. Xu Xiaoyang, the chief strategy officer of the Group, presided over the meeting, and the senior management of the Group attended the seminar online or offline, and more than 50 heads of related enterprises and business backbones of the Group attended the meeting.

In the past few decades, India has accumulated rich experience in global expansion, and gradually formed a consensus on the route of internationalization of enterprises, formed a perfect business model and supply chain, and has strong international competitiveness; At present, the overseas market has accounted for more than half of the total scale of its pharmaceutical business. In recent years, China's pharmaceutical reform and market opening have attracted the attention of Indian enterprises, and they regarded China market as the strategic development direction in the next few years.

Facing the complicated international political situation, the internationalization of pharmaceutical enterprises in China still faces both challenges and opportunities, and Indian enterprises have provided good experience for reference. In recent years, China has promoted the reform of pharmaceutical industry, promoted the consistency evaluation of drugs, successfully joined ICH and applied to join PIC/S. A series of measures have helped Chinese pharmaceutical enterprises' global expansion. It is also a good choice for enterprises to expand their global market by cooperating with pharmaceutical capital and building an overseas industrial ecology.